Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024. In the quarter to June 2026, revenue grew 18.5%, EPS grew 14.3%, free cash flow grew 74.2% and total debt rose 1.43%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow TKNO
Alpha Teknova, Inc. (TKNO) Altman Z-score
Alpha Teknova, Inc.'s Altman Z-score for fiscal 2025 is 1.83, in the grey zone (1.81–2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 1.83 | (3.12) |
| FY2024 | 4.95 | 4.39 |
| FY2023 | 0.56 | (0.34) |
| FY2022 | 0.90 | (8.17) |
| FY2021 | 9.08 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.26 | — | 0.31 | |
| Retained earnings / total assets | (1.31) | — | −1.84 | |
| EBIT / total assets | (0.16) | — | −0.54 | |
| Market value of equity / total liabilities | 5.84 | — | 3.50 | |
| Sales / total assets | 0.39 | — | 0.39 | |
| Altman Z-score | Grey zone | 1.83 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −1.59 | ||
Z and Z″ put Alpha Teknova, Inc. in different zones: grey zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KMDA Kamada Ltd. compare | 3.3× |
| ANIK Anika Therapeutics Inc. compare | 3.1× |
| TKNO Alpha Teknova, Inc. | 1.8× |
| EBS Emergent Biosolutions Inc. compare | 1.6× |
| EVO Evotec AG compare | 0.6× |
| EOLS Evolus, Inc. compare | −1.9× |
| TLRY Tilray Brands, Inc. compare | −2.0× |
| AQST Aquestive Therapeutics, Inc. compare | −2.2× |
| CGC Canopy Growth Corporation compare | −13.2× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets